Skip to main content
main-content
Top

12-22-2020 | Diagnosis | News

News in brief

Regression to mean accounts for many remissions from apparent type 2 diabetes

Author: Eleanor McDermid

share
SHARE
print
PRINT
insite
SEARCH

medwireNews: A large number of people diagnosed with type 2 diabetes achieve intermediate or even normal glucose levels within the following few years, with regression to the mean accounting for more than half of these remissions, research suggests.

Writing in Diabetes Care, Maria Inês Schmidt (Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil) and study co-authors therefore emphasize the importance of repeating glucose tests in people thought to have diabetes.

“Although clinicians in busy day-to-day practice may skip confirmation, our findings illustrate that lack of confirmation will result in a large proportion of individuals receiving pharmacological treatment who do not really have diabetes,” they say.

The team identified 526 people, from 11,645 participants of the ELSA-Brasil longitudinal cohort study, who were newly diagnosed with type 2 diabetes on the basis of oral glucose tolerance testing and glycated hemoglobin level.

When repeated after an average of 3.84 years, 49.4% of these people had regressed, mostly to intermediate hyperglycemia, although 4.9% had normoglycemia. But regression to the mean accounted for more than half of this – after adjusting for this effect, the proportion who regressed was a considerably smaller 20.2%.

Some of this remaining proportion was accounted for by improvements in glucose homeostasis (indicated by the disposition index) and by weight loss.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group

Diabetes Care 2020; doi:10.2337/dc20-2030

share
SHARE
print
PRINT

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

GLP-1 receptor agonists

Browse the latest news, clinical trial updates, and expert commentary.